http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Improvement of lower hybrid current drive systems for high-power and long-pulse operation on EAST
Wang M.,Liu L.,Zhao L.M.,Li M.H.,Ma W.D.,Hu H.C.,Wu Z.G.,Feng J.Q.,Yang Y.,Zhu L.,Chen M.,Zhou T.A.,Jia H.,Zhang J.,Cao L.,Zhang L.,Liang R.R.,Ding B.J.,Zhang X.J.,Shan J.F.,Liu F.K.,Ekedahl A.,Gonich 한국원자력학회 2022 Nuclear Engineering and Technology Vol.54 No.11
Aiming at high-power and long-pulse operation up to 1000 s, some improvements have been made for both 2.45 GHz and 4.6 GHz lower hybrid (LH) systems during the recent 5 years. At first, the guard limiters of the LH antennas with graphite tiles were upgraded to tungsten, the most promising material for plasma facing components in nuclear fusion devices. These new guard limiters can operate at a peak power density of 12.9 MW/m2 . Strong hot spots were usually observed on the old graphite limiters when 4.6 GHz system operated with power >2.0 MW [B. N. Wan et al., Nucl. Fusion 57 (2017) 102019], leading to a reduction of the maximum power capability. With the new limiters, 4.6 GHz LH system, the main current drive (CD) and electron heating tool for EAST, can be operated with power >2.5 MW routinely. Long-pulse operation up to 100 s with 4.6 GHz LH power of 2.4 MW was achieved in 2021 and the maximal temperature on the guard limiters measured by an infrared (IR) camera was about 540 C, much below the permissible value of tungsten material (~1200 C). A discharge with a duration of 1056 s was achieved and the 4.6 GHz LH energy injected into the plasma was up to 1.05 GJ. Secondly, the fully-activemultijunction (FAM) launcher of 2.45 GHz system was upgraded to a passive-active-multijunction (PAM), for which the density of optimum coupling was relatively low (below the cut-off value). Good coupling with reflection coefficient ~3% has been achieved with plasma-antenna distance up to 11 cm for the new PAM. Finally, in order to eliminate the effect of ion cyclotron range of frequencies (ICRF) wave on 4.6 GHz LH wave coupling, the location of the ICRF launcher was changed to a port that is located 157.5 toroidally from the 4.6 GHz LH system and is not magnetically connected
Wang, J.,Wang, S.,Zhang, W.,Wang, X.,Liu, X.,Liu, L.,Li, L.,Liang, Y.,Yu, J.,Jeong, L.S.,Jia, L.,Zhao, H.,Zhang, Y. Academic Press 2017 Biochemical and biophysical research communication Vol. No.
Inhibition of protein neddylation pathway has emerged an attractive anticancer strategy in preclinical studies by using Nedd8-activating enzyme (NAE) inhibitor MLN4924 (Pevonedistat). Previous studies have reported the antitumor activity of MLN4924 mediated by its efficacy on apoptosis, autophagy and senescence. However, whether MLN4924 has any effect on renal carcinoma cells (RCC) remains unexplored. Here we reported that MLN4924 specifically inhibited protein neddylation pathway, leading to statistically significantly suppress the proliferation, survival and migration of RCC cells by inducing G<SUB>2</SUB> cell-cycle arrest, followed by apoptosis in a MLN4924 dose-dependent manner. Further mechanistic study revealed that MLN4924-induced apoptosis was mediated by substantial up-regulation of pro-apoptotic NOXA. These findings highlighted the anticancer effects of the neddylation inhibitors (e.g. MLN4924) for the treatment of RCC.
( L. Wei ),( F. Wang ),( M. Zhang ),( J. Jia ),( A.A. Yakovlev ),( W. Xie ),( E.Z. Burnevich ),( J. Niu ),( Y.J. Jung ),( X. Jiang ),( M. Xu ),( X. Chen ),( Q. Xie ),( J. Li ),( J. Hou ),( H. Tang ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Background/Aims: Treatment-naive GT 1b-infected patients from mainland China, South Korea and Russia were assessed for SVR at follow-up week 12 (SVR12) after receiving daclatasvir (60 mg, QD) and asunaprevir (100 mg, BID) (DCV+ASV). Methods: Patients were randomized 3:1 to receive DCV+ASV (24 weeks; immediate treatment [IM]) or 12 weeks of placebo followed by DCV+ASV (24 weeks; placebo-deferred treatment [PD]). The primary endpoint was to evaluate SVR12 in the IM arm to the historical rate for peginterferon/ribavirin (70%). Secondary endpoints included overall safety and safety comparisons between the treatment arms during the first 12 weeks. Results: 207 patients were randomized to IM (n=155) or PD (n=52); Asian (86%), female (59%), IL28B CC genotype (68%) and median age 49 (range 18-73) years; cirrhosis (13%), HCV RNA ≥6x106 IU/mL (53%). SVR12 in the IM arm was 92% and broadly unaffected by most baseline factors assessed (Figure); SVR12 was higher in patients without (96%) baseline NS5A-L31M/V or Y93H polymorphisms. There were 6 virologic breakthroughs, 6 relapses and 1 detectable HCV RNA at end-of-treatment in the IM arm. Safety was mostly comparable between the two arms during the first 12 weeks. The most frequent adverse events (AEs; ≥5%) during DCV+ASV (24 weeks) treatment in both arms were aminotransferase, bilirubin and INR elevations, hypertension, fatigue and respiratory tract infections; the most frequent treatment-emergent grade 3/4 laboratory abnormalities were aminotransferase (≤4.5%) and hematologic, lipase and total bilirubin abnormalities (≤2%); one patient (IM) discontinued DCV+ASV for aminotransferase elevations, nausea and jaundice (all reversible); one patient PD) discontinued DCV+ASV for a fatal AE unrelated to treatment. Conclusions: These data demonstrate that DCV+ASV is a highly efficacious and well tolerated treatment for treatment-naive HCV GT 1b-infected patients. Those treated immediately with DCV+ASV achieved a 92% SVR12 rate which was unaffected by factors known to attenuate response to interferon.
Jia, Yuefa,Wu, Changjin,Kim, Deok-Hyeon,Lee, B.W.,Rhee, S.J.,Park, Yun Chang,Kim, Chul Sung,Wang, Q.J.,Liu, Chunli Elsevier 2018 CHEMICAL ENGINEERING JOURNAL -LAUSANNE- Vol.337 No.-
<P><B>Abstract</B></P> <P>In the present work, N doped BiFeO<SUB>3</SUB> (N-BFO) nanoparticles have been synthesized via a sol-gel rapid calcination technique using melamine (C<SUB>3</SUB>H<SUB>6</SUB>N<SUB>6</SUB>) as the N precursor. It is found that N-doping could effectively narrow the band gap of BFO, which obviously enhanced the visible light adsorption capability. Meanwhile, N-doping could lead to significant increase in the magnetization of BFO. Particularly, the saturation magnetization (<I>M<SUB>s</SUB> </I>) was increased up to 0.35 emu/g (as compared to that of pure BFO: 0.07 emu/g) when 12.5 mmol N doping precursor was used (12.5N-BFO). The catalytic performance of N-BFO nanoparticles was evaluated through the degradation of bisphenol A (BPA) under visible light irradiation. 12.5N-BFO was found to be an efficient catalyst of BPA, and the addition of H<SUB>2</SUB>O<SUB>2</SUB> (10 mmol/L) or H<SUB>2</SUB>O<SUB>2</SUB> (10 mmol/L)/<SMALL>L</SMALL>-cysteine (0.25 mmol/L) can further enhance the degradation efficiency up to 60% and 94% within 120 min, respectively. The 12.5N-BFO nanoparticles were very stable during photocatalytic processes and their photo-Fenton catalytic activity can be retained even after three recycling processes.</P> <P><B>Highlights</B></P> <P> <UL> <LI> N doped BiFeO<SUB>3</SUB> have been synthesized using melamine as the N precursor. </LI> <LI> The band gap and saturation magnetization of N doped BiFeO<SUB>3</SUB> is tunable. </LI> <LI> N doped BiFeO<SUB>3</SUB>/H<SUB>2</SUB>O<SUB>2</SUB> shows enhanced efficient degradation of bisphenol A. </LI> <LI> Addition of <SMALL>L</SMALL>-cysteine can further enhanced photodegradation performance. </LI> <LI> A mechanism of bisphenol A degradation was proposed. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Observation of a vector charmoniumlike state in e+e−→Ds+Ds1(2536)−+c.c.
Jia, S.,Shen, C. P.,Yuan, C. Z.,Wang, X. L.,Adachi, I.,Aihara, H.,Asner, D. M.,Atmacan, H.,Aulchenko, V.,Ayad, R.,Babu, V.,Badhrees, I.,Bakich, A. M.,Behera, P.,Bhuyan, B.,Bilka, T.,Biswal, J.,Bobrov, American Physical Society 2019 Physical review. D Vol.100 No.11
Jia-Bao Yan,J.Y. Richard Liew,Min-Hong Zhang,Junyan Wang 국제구조공학회 2014 Steel and Composite Structures, An International J Vol.17 No.6
Ultra-lightweight cement composite (ULCC) with a compressive strength of 60 MPa and density of 1450 kg/m³ has been developed and used in the steel-concrete-steel (SCS) sandwich structures. ULCC was adopted as the core material in the SCS sandwich composite beams to reduce the overall structural weight. Headed shear studs working in pairs with overlapped lengths were used to achieve composite action between the core material and steel face plates. Nine quasi-static tests on this type of SCS sandwich composite beams were carried out to evaluate their ultimate strength performances. Different parameters influencing the ultimate strength of the SCS sandwich composite beams were studied and discussed. Design equations were developed to predict the ultimate resistance of the cross section due to pure bending, pure shear and combined action between shear and moment. Effective stiffness of the sandwich composite beam section is also derived to predict the elastic deflection under service load. Finally, the design equations were validated by the test results.
Wang, Zehua,Yang, Bo,Zhang, Min,Guo, Weiwei,Wu, Zhiyuan,Wang, Yue,Jia, Lin,Li, Song,Caesar-Johnson, Samantha J.,Demchok, John A.,Felau, Ina,Kasapi, Melpomeni,Ferguson, Martin L.,Hutter, Carolyn M.,Sof Cell Press 2018 Cancer Cell Vol. No.
<P><B>Summary</B></P> <P>We characterized the epigenetic landscape of genes encoding long noncoding RNAs (lncRNAs) across 6,475 tumors and 455 cancer cell lines. In stark contrast to the CpG island hypermethylation phenotype in cancer, we observed a recurrent hypomethylation of 1,006 lncRNA genes in cancer, including <I>EPIC1</I> (epigenetically-induced lncRNA1). Overexpression of <I>EPIC1</I> is associated with poor prognosis in luminal B breast cancer patients and enhances tumor growth <I>in vitro</I> and <I>in vivo.</I> Mechanistically, <I>EPIC1</I> promotes cell-cycle progression by interacting with MYC through <I>EPIC1</I>'s 129–283 nt region. <I>EPIC1</I> knockdown reduces the occupancy of MYC to its target genes (e.g., <I>CDKN1A</I>, <I>CCNA2</I>, <I>CDC20</I>, and <I>CDC45</I>). MYC depletion abolishes <I>EPIC1</I>'s regulation of MYC target and luminal breast cancer tumorigenesis <I>in vitro</I> and <I>in vivo</I>.</P> <P><B>Highlights</B></P> <P> <UL> <LI> LncRNAs show a hypomethylation phenotype, in contrast to a CIMP phenotype in cancer </LI> <LI> <I>EPIC1</I> promotes breast tumorigenesis through regulating cancer cell-cycle progression </LI> <LI> <I>EPIC1</I> directly interacts with MYC protein through <I>EPIC1</I>'s 129–283 nt region </LI> <LI> <I>EPIC1</I> regulates MYC targets by enhancing MYC occupancy on its target promoters </LI> </UL> </P> <P><B>Graphical Abstract</B></P> <P>[DISPLAY OMISSION]</P>